NewslettersHuman Immunology NewsQuell Therapeutics Achieves Milestone for Type 1 Diabetes CAR-Treg Cell Therapy ProgramBy Jamie Kang - November 19, 2024044Quell Therapeutics, Ltd. announces that AstraZeneca has selected a candidate to progress in the Type 1 Diabetes Treg cell therapy program.[Quell Therapeutics, Ltd. (Globe Newswire)]Press Release